the aid library

LIST OPTIONS

Filter

2195

Sort by:

Direction:

Download (1458)

View PDF (2106)

WHO guidelines on safety monitoring of herbal medicines in pharmacovigilance systems

World Health Organization WHO (2004) C_WHO

Guidelines

Download (640)

View PDF (760)

Sierra Leone: A Guide for Detecting and Reporting adverse Drug Reactions

Drug Safety Monitoring Programme; Pharmacy Board Sierra Leone; Ministry of Health and Sanitation Sierra Leone (2005) C1

Download (4582)

View PDF (2661)

Guideline for Adverse Drug Events Monitoring (Pharmacovigilance), Ethiopia

Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA) (2014) C1

3rd edition

Download (343)

View PDF (729)

National Guidelines and Operational Manual for Programmatic Management of Drug Resistant TB (PMDT), 2nd ed.

Government of the People’s Republic of Bangladesh, Directorate General of Health Services (2013) C1

Specific measures are being taken within the National Tuberculosis Control Programme (NTP) to address the MDR TB problem through appropriate management of patients and strategies to prevent the propagation and dissemination of MDR TB.
The term "Programmatic Management of Drug Resistant TB" (PMD... more

Download (323)

View PDF (323)

Expansion Plan of Programmatic Management of Drug Resistant TB (PMDT)

National TB Control Programme, Bangladesh World Health Organization WHO, Bangladesh (2013) C1

Download (135)

View PDF (248)

Serbia National Drug Report 2017

European Monitoring Centre for Drugs and Drug Addiction; Republic of Serbia Ministry of Health (2017) C2

Download (326)

View PDF (509)

Guidelines for the Management of Multidrug-Resistant Tuberculosis (MDR-TB) in Myanmar

The Republic of the Union of Myanmar, Ministry of Health, Department of Health, National Tuberculosis Programme (2013) C_WHO

Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant TB has been developed and forms part of the Five Year National Strateg... more

Download (2765)

View PDF (3530)

Safety Monitoring of medicinal products

Uppsala Monitoring Centre World Health Organization (2012) C_WHO

Reporting system for the general public - This document aims to provide practical guidelines on how to set up national systems for consumers to report adverse reactions to medicines. The purpose is to help countries set up a well-organized and effective consumer reporting system within their pharmac... more

Download (252)

View PDF (472)

Active tuberculosis drug-safety monitoring and management (aDSM)

World Health Organization (2015) C_WHO

Framework for implementation. The END TB Strategy.

Download (176)

View PDF (234)

Albania National Drug Report 2017

European Monitoring Centre for Drugs and Drug Addiction; Instituti Shendetit Public European Monitoring Centre for Drugs and Drug Addiction; Instituti Shendetit Public (2017) C2

Download (260)

View PDF (379)

WHO recommendations on active drug safety management and monitoring (aDSM) for new drugs and regimens

D. Falzon, USAID, Asia Regional Pharmacovigilance World Health Organization (2017) C_WHO

Download (537)

View PDF (807)

Nambia: NATIONAL GUIDELINES FOR MEDICINES SAFETY SURVEILLANCE

Ministry of Health and Social Services (MOHSS) (2011) C2

Therapeutics Information and Pharmacovigilance Centre | TIPC

Download (590)

View PDF (943)

GUIDELINES FOR DETECTING AND REPORTING ADVERSE DRUG OR VACCINE REACTIONS AND EVENTS IN ZAMBIA

Zambia Medicines Regulatory Authority (ZAMRA) (2006) C2

The safety of medicines in Zambia - why health workers need to take action | Produced by the National Pharmacovigilance Unit (NPVU)

Download (1040)

View PDF (786)

Tanzania: National Guidelines for Monitoring Medicines Safety

Tanzania Food & Drugs Authority (TFDA) (2010) C2

Made under Section 5 (c) of the Tanzania Food, Drugs and Cosmetics Act, 2003 | Second Edition

Download (82)

View PDF (115)

Monitoring HIV impact using population-based surveys

UNAIDS (Joint United Nations Programme on HIVAIDS); World Health Organization (WHO) UNAIDS (Joint United Nations Programme on HIVAIDS); World Health Organization (WHO) (2015) C2

UNAIDS/WHO Working group HIV/AIDS and STI surveillance 2015 / Reference

Download (108)

View PDF (150)

WHO guidelines on hand hygiene in health care: a summary

World Health Organization WHO (2009) C_WHO

Confronted with the important issue of patient safety, in 2002 the Fifty-fifth World Health Assembly adopted a resolution urging countries to pay the closest possible attention to the problem and to strengthen safety and monitoring systems. In May 2004, the Fifty-seventh World Health Assembly approv... more

Download (159)

View PDF (168)

The Importance of Pharmacovigilance

World Health Organization WHO (2020) C_WHO

The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug... more

Download (402)

View PDF (728)

Safety in administering medicines for neglected tropical diseases

World Health Organization WHO (2021) C_WHO

This manual summarizes key issues related to the safety of NTD medicines and their administration, with a focus on essential medicines used in mass drug administration (MDA), also called preventive chemotherapy. It can be used as a standalone reference manual, but is intended to be used in conjuncti... more

Download (155)

View PDF (178)

WHO pharmaceuticals newsletter - No. 1, 2023

World Health Organisation (WHO) (2023) C_WHO

The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicinal products and regulatory actions taken by authorities around the world. In addition, this edition includes summary and recommendations from the virtual meeting of the members of the WHO Programme f... more

Download (186)

View PDF (174)

Guidance to facilitate monitoring and evaluation for antimicrobial resistance national action plans

Quadripartite: Food and Agriculture Organization of the United Nations FAO; UN Environment Programme UNEP; World Health Organization WHO; World Organisation for Animal Health WAHO (2023) CC

Antimicrobial resistance (AMR) is a global human, animal, plant and environment health threat that needs to be addressed by every country. The impacts of AMR are wide-ranging in terms of human health, animal health, food security and safety, environmental effects on ecosystems and biodiversity, and ...socioeconomic development. Just like the climate crisis, AMR poses a significant threat to the delivery of the 2030 Agenda for Sustainable Development. The response to the AMR crisis has been spearheaded through the global action plan on antimicrobial resistance (GAP-AMR), developed by the World Health Organization (WHO) in 2015, in close collaboration with the Food and Agriculture Organization of the United Nations (FAO) and the World Organisation for Animal Health (WOAH), and formally endorsed by the three organizations’ governing bodies and by the Political Declaration of the high-level meeting of the United Nations General Assembly on AMR in 2016. In 2022, the three organizations officially became the Quadripartite by welcoming the United Nations Environment Programme (UNEP) into the alliance “to accelerate coordination strategy on human, animal and ecosystem health”. The aim of the GAP-AMR is to ensure the continuity of successful treatment with effective and safe medicines. Its strategic objectives include: • improving the awareness and understanding of AMR; • strengthening the knowledge and evidence base through surveillance and research; • reducing the incidence of infection through effective sanitation, hygiene and infection prevention measures; optimizing the use of antimicrobial medicines in human and animal health; and • developing the economic case for sustainable investment that takes account of the needs of all countries and increasing investment in new medicines, diagnostic tools, vaccines and other interventions. With the adoption of the GAP-AMR, countries agreed to develop national action plans (NAPs) aligned with the GAP-AMR to mainstream AMR interventions nationally. Individually, the Quadripartite took action to advance AMR interventions in their respective sectors. FAO adopted a resolution on AMR recognizing that it poses an increasingly serious threat to public health and sustainable food production, and developed an AMR action plan to support the resolution’s implementation. For its part, WOAH developed a strategy on AMR aligned with the GAP-AMR, acknowledging the importance of a One Health approach to AMR. Similarly, more recently, UNEP’s governing body, the United Nations Environment Assembly, recognized that AMR is a current and increasing threat and a challenge to global health, food security and the sustainable development of all countries, and welcomed the GAP-AMR and the NAPs developed in accordance with its five overarching strategic objectives more